JP2021522173A5 - - Google Patents

Info

Publication number
JP2021522173A5
JP2021522173A5 JP2020557222A JP2020557222A JP2021522173A5 JP 2021522173 A5 JP2021522173 A5 JP 2021522173A5 JP 2020557222 A JP2020557222 A JP 2020557222A JP 2020557222 A JP2020557222 A JP 2020557222A JP 2021522173 A5 JP2021522173 A5 JP 2021522173A5
Authority
JP
Japan
Prior art keywords
promoter
composition according
subject
virus
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020557222A
Other languages
English (en)
Japanese (ja)
Other versions
JP7769355B2 (ja
JP2021522173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028108 external-priority patent/WO2019204593A1/en
Publication of JP2021522173A publication Critical patent/JP2021522173A/ja
Publication of JP2021522173A5 publication Critical patent/JP2021522173A5/ja
Application granted granted Critical
Publication of JP7769355B2 publication Critical patent/JP7769355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020557222A 2018-04-18 2019-04-18 ミトコンドリアｄｎａ枯渇症候群を含む不均衡ヌクレオチドプールに起因する疾患の遺伝子治療 Active JP7769355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659281P 2018-04-18 2018-04-18
US62/659,281 2018-04-18
PCT/US2019/028108 WO2019204593A1 (en) 2018-04-18 2019-04-18 Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes

Publications (3)

Publication Number Publication Date
JP2021522173A JP2021522173A (ja) 2021-08-30
JP2021522173A5 true JP2021522173A5 (enExample) 2022-04-18
JP7769355B2 JP7769355B2 (ja) 2025-11-13

Family

ID=68239912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020557222A Active JP7769355B2 (ja) 2018-04-18 2019-04-18 ミトコンドリアｄｎａ枯渇症候群を含む不均衡ヌクレオチドプールに起因する疾患の遺伝子治療

Country Status (13)

Country Link
US (1) US12419970B2 (enExample)
EP (1) EP3781671A4 (enExample)
JP (1) JP7769355B2 (enExample)
KR (1) KR20210009317A (enExample)
CN (1) CN112312929A (enExample)
AU (1) AU2019255745A1 (enExample)
BR (1) BR112020021324A2 (enExample)
CA (1) CA3097392A1 (enExample)
CL (1) CL2020002704A1 (enExample)
CO (1) CO2020014193A2 (enExample)
IL (1) IL278130B1 (enExample)
MX (1) MX2020010994A (enExample)
WO (1) WO2019204593A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US20220403417A1 (en) * 2019-11-20 2022-12-22 University Of Massachusetts Aav-based delivery of thymine kinase 2
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) * 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
CN121443327A (zh) * 2023-06-30 2026-01-30 社会福祉法人 三星生命公益财团 包含搭载水螅NDi1的重组腺相关病毒载体的用于预防、改善或治疗线粒体复合物1异常疾病的组合物
CN120060299B (zh) * 2025-02-21 2025-11-28 三峡大学 一种密码子优化的twnk基因、腺相关病毒载体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5843742A (en) 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
AU2007234698B2 (en) * 2006-04-07 2013-08-01 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
LT3505174T (lt) 2015-06-17 2020-09-10 The Trustees Of Columbia University In The City Of New York Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Similar Documents

Publication Publication Date Title
JP2021522173A5 (enExample)
JP2021512649A5 (enExample)
JP2022508182A5 (enExample)
JP2022529631A5 (enExample)
JP2022549140A5 (enExample)
JP2020513811A5 (enExample)
JP2020522269A5 (enExample)
JP2019511570A5 (enExample)
JP2018148927A5 (enExample)
JP2017533715A5 (enExample)
JP2021522836A5 (enExample)
RU2018140499A (ru) Способы и композиции для лечения хореи гентингтона
JP2021500352A5 (enExample)
JP2020510447A5 (enExample)
JP2023537358A5 (enExample)
JP2023537980A5 (enExample)
ES3057171T3 (en) Peptide-modified aav capsid with enhanced muscle transduction efficiency
JP2023515692A5 (enExample)
JP2023551873A5 (enExample)
JP2022551744A5 (enExample)
JP2024512483A5 (enExample)
JP2023524414A5 (enExample)
JP2024119900A5 (enExample)
JP2021520811A5 (enExample)
JP2023529371A5 (enExample)